|
A.S. Tabatabaei-Panah, Ph.D., A.H. Zarnani, D.M.T, Ph.D., Sh. Montaser-Kouhsari,
Ph.D.,
M. Chamankhah, Ph.D., R. Ghods, M.Sc., A.A. Bayat, B.Sc., G.E. Kazemi-Sefat,
B.Sc.,
S.A.R. Mahmoudi, M.Sc., M. Ostad Karampour, M.Sc., S. Shojaeian, M.Sc.,
M. Jeddi-Tehrani, Ph.D.*
* Corresponding Corresponding Address:
P.O.Box: 1985713831, Monoclonal Antibody Research Center, Avicenna Research
Institute, Tehran, Iran
Email: mahjed@yahoo.com
|
|
Received: 9/Dec/2007, Accepted: 13/Feb/2008
Objective: Breast cancer is the most common cancer among women in the world.
Early diagnosis of this cancer is a key element for its treatment. One of the
approaches for diagnosis of breast cancer is detection of its tumour-associated
markers. Hence, Her2 has been the main focus of the researches in the field.
Materials and Methods: For diagnosis of Her2 overexpression, monoclonal
antibodies (mAb) reacting against Her2 were produced in this study. For this
purpose, two peptides from extracellular domain of Her2 were selected and the
mAbs reacting against them were produced by hybrodoma technology. Reactivity of
these antibodies were then evaluated in different immunological assays including
ELISA, Immunoflurescence (IF), western blot (WB) and immunoprecipitation (IP).
Results: Total of 5 clones were produced from two separate fusions, and
antibody isotyping revealed that all clones were IgM. These mAbs showed
appropriate reactivities in the following assays: ELISA, immunofluresence by
staining of breast cancer cell line (SKBR3), WB and IP by detecting the 185 KD
band of Her2.
Conclusion: In conclusion, it seems that the mAbs are useful diagnostic
tools for detection of Her2 expression in patients with breast cancer.
Keywords: Breast Cancer, Her2, Monoclonal Antibody, ELISA,
Immunofluresence, Immunoprecipitation |
|